These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2056329)

  • 1. Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.
    Ray-Chaudhuri K; Abbott RJ; Millac PA
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):372-3. PubMed ID: 2056329
    [No Abstract]   [Full Text] [Related]  

  • 2. Unexpected findings with apomorphine and their possible consequences.
    Cotzias GC; Mena I; Papavasiliou PS; Mendez J
    Adv Neurol; 1974; 5():295-9. PubMed ID: 4440577
    [No Abstract]   [Full Text] [Related]  

  • 3. [Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement].
    Trenkwalder C; Boesch S; Ceballos-Baumann A; Dressler D; Eggert K; Gasser T; Honig H; Müller T; Reichmann H; Sieb JP; Storch A; Odin P; Poewe W
    Nervenarzt; 2008 Apr; 79(4):475-9. PubMed ID: 18210043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous apomorphine in the treatment of Parkinson's disease.
    Frankel JP; Lees AJ; Kempster PA; Stern GM
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):96-101. PubMed ID: 2313313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
    Poewe W; Kleedorfer B; Wagner M; Bösch S; Schelosky L
    Adv Neurol; 1993; 60():656-9. PubMed ID: 8420206
    [No Abstract]   [Full Text] [Related]  

  • 6. [Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease].
    Kreczy-Kleedorfer B; Wagner M; Bösch S; Poewe W
    Nervenarzt; 1993 Apr; 64(4):221-5. PubMed ID: 8506009
    [No Abstract]   [Full Text] [Related]  

  • 7. The motor response to sequential apomorphine in parkinsonian fluctuations.
    Hughes AJ; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):358-60. PubMed ID: 2056323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Apomorphine as adjuvant treatment in idiopathic Parkinson syndrome].
    Bösch MF; Ludin HP
    Schweiz Arch Neurol Psychiatr (1985); 1994; 145(5):8-13. PubMed ID: 7709189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
    Merello M; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1024-6. PubMed ID: 1469397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results.
    Stocchi F; Vacca L; De Pandis MF; Barbato L; Valente M; Ruggieri S
    Neurol Sci; 2001 Feb; 22(1):93-4. PubMed ID: 11487217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Side-effects of subcutaneous apomorphine in Parkinson's disease.
    Ruggieri S; Stocchi F; Carta A; Agnoli A
    Lancet; 1989 Mar; 1(8637):566. PubMed ID: 2564106
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Apomorphine test in Parkinson disease--dose and corresponding parameters].
    Pinter MM; Helscher RJ; Sattler AP
    Wien Klin Wochenschr; 1993; 105(16):472-5. PubMed ID: 8212705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
    Kempster PA; Frankel JP; Stern GM; Lees AJ
    J Neurol Neurosurg Psychiatry; 1990 Nov; 53(11):1004-7. PubMed ID: 2283512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
    Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM
    Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical use of apomorphine in Parkinson's disease.
    Steiger MJ; Quinn NP; Marsden CD
    J Neurol; 1992 Aug; 239(7):389-93. PubMed ID: 1403022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical akinetic response to apomorphine in parkinsonism.
    Jenkins JR; Pearce JM
    J Neurol Neurosurg Psychiatry; 1992 May; 55(5):414-5. PubMed ID: 1602324
    [No Abstract]   [Full Text] [Related]  

  • 20. Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication.
    Deutschländer A; Asmus F; Marelli E; Klopstock T; Gasser T; Bötzel K
    Mov Disord; 2006 Sep; 21(9):1523-5. PubMed ID: 16755578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.